IP Library Granted Patent US 11,331,267
Granted Patent B2
US 11,331,267 · App. 17/483,220 · Granted May 17, 2022

Sustained release biodegradable intracanalicular inserts comprising a hydrogel and cyclosporine

Inventors: Charles D. Blizzard (Nashua, NH); Rami El-Hayek (Norwood, MA); Michael Goldstein (Cambridge, MA); Peter Jarrett (Burlington, MA); Andrew Vanslette (Bolton, MA)
Assignee: Ocular Therapeutix, Inc.
A61K9/0051A61K38/13A61K47/10A61K47/22
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,331,267
App. No.
17/483,220
Granted
May 17, 2022
Kind
B2
Abstract

Provided herein are sustained release biodegradable intracanalicular insert comprising a hydrogel and cyclosporine, methods of treating or preventing an ocular disease in a subject in need thereof by administering such inserts as well as methods of manufacturing such inserts.

Claims (29)

1. A sustained release biodegradable intracanalicular insert comprising a hydrogel and cyclosporine, wherein the cyclosporine is in the form of particles and wherein the cyclosporine particles are dispersed within the hydrogel, wherein the hydrogel comprises a polymer network comprising crosslinked polymer units that are identical or different which are polyethylene glycol units having four arms, wherein the four arms of the 4-arm polyethylene glycol units are connected to a core molecule of pentaerythritol, the polymer network is formed by reacting an electrophilic group-containing multi-arm polymer precursor with a nucleophilic group-containing cross-linking agent, the electrophilic group is an N-hydroxysuccinimidyl (NHS) ester group, the nucleophilic group-containing crosslinking agent is a small molecule amine with a molecular weight below 1,000 Da, and the nucleophilic group-containing crosslinking agent is a labeled trilysine.

2. The sustained release biodegradable intracanalicular insert of claim 1 , wherein the cyclosporine particles have a d50 value of less than about 50 μm.

3. The sustained release biodegradable intracanalicular insert of claim 2 , wherein the cyclosporine particles have a d50 value ranging from 3 to 17 μm.

4. The sustained release biodegradable intracanalicular insert of claim 1 , wherein the polymer network comprises polyethylene glycol units having an average molecular weight in the range from about 2,000 to about 100,000 Daltons.

5. The sustained release biodegradable intracanalicular insert of claim 1 , wherein the multi-arm polymer units comprise 4a20kPEG units and the cross-linking units comprise fluorescein-conjugated trilysine amide units.

6. A The sustained release biodegradable intracanalicular insert of claim 1 , wherein the polymer network is obtained by reacting 4a20kPEG-SG or 4a20kPEG-SAP with fluorescein-conjugated trilysine in a molar ratio ranging from about 1:2 to about 2:1.

7. The sustained release biodegradable intracanalicular insert of claim 1 , wherein the insert in a dried state contains from about 15% to about 80% by weight of the cyclosporine based on the total weight of the insert and from about 20% to about 60% by weight polymer units based on the total weight of the insert.

8. A sustained release biodegradable intracanalicular insert comprising according to claim 1 a hydrogel and cyclosporine, wherein the insert in a dried state contains from about 40% to about 80% by weight of the cyclosporine based on the total weight of the insert.

9. The sustained release biodegradable intracanalicular insert of claim 8 , wherein the insert in a dried state contains from 45% to 55% by weight of the cyclosporine based on the total weight of the insert.

10. The sustained release biodegradable intracanalicular insert of claim 1 , wherein the insert contains a surfactant.

11. The sustained release biodegradable intracanalicular insert of claim 9 , wherein the insert contains a surfactant.

12. The sustained release biodegradable intracanalicular insert of claim 11 , wherein the insert in a dried state contains from about 0.01% to about 5% by weight of a surfactant based on the total weight of the insert.

13. The sustained release biodegradable intracanalicular insert of claim 12 , wherein the insert contains a non-ionic surfactant.

14. The sustained release biodegradable intracanalicular insert of claim 13 , wherein the cyclosporine content as measured by HPLC after at least 3 months at a temperature of from 2 to 8° C. is from about 300 to about 410 μg by weight.

15. The sustained release biodegradable intracanalicular insert of any claim 14 , wherein the amount of impurities as measured by HPLC after at least 3 months of storage at a temperature of from 2 to 8° C. is not more than 3.0%.

16. The sustained release biodegradable intracanalicular insert of claim 15 , wherein the insert is in the form of a fiber, wherein the fiber has an average length of about 1.5 mm to about 4.0 mm and an average diameter of not more than 0.8 mm in its dried state.

17. The sustained release biodegradable intracanalicular insert of claim 16 , wherein the insert after at least 3 months at a temperature of from 2 to 8° C. is in the form of a fiber that has an average length of about 2.5 mm to about 2.9 mm and an average diameter of not more than 0.62 mm in its dried state.

18. The sustained release biodegradable intracanalicular insert of claim 17 , wherein the insert is in the form of a fiber that has an average diameter of at least 1.0 mm in expanded state after 10 minutes of hydration or of at least 1.3 mm in equilibrium state after 24 hours of hydration in vitro in phosphate-buffered saline at a pH of 7.4 at 37° C.

19. The sustained release biodegradable intracanalicular insert of claim 18 , wherein the insert disintegrates in the canaliculus within about 1 to about 6 months after insertion.

20. The sustained release biodegradable intracanalicular insert of claim 19 , wherein the insert after insertion to the canaliculus releases a therapeutically effective amount of cyclosporine over a period of at least about 1 month after insertion.

21. The sustained release biodegradable intracanalicular insert of claim 20 , wherein cyclosporine is released from the insert after insertion to a human subject at an average rate of about 0.1 μg/day to about 10 μg/day.

22. A sustained release biodegradable intracanalicular insert comprising according to claim 1

a hydrogel comprising a polymer network obtained by reacting 4a20kPEG-SG with fluorescein-conjugated trilysine in a molar ratio of about 1:1

and cyclosporine in an amount of about 360 μg,

in the form of a fiber that has an average length of about 2.5 mm to about 2.9 mm and an average diameter of not more than 0.62 mm in its dried state.

23. A sustained release biodegradable intracanalicular insert comprising according to claim 1

a hydrogel comprising a polymer network obtained by reacting 4a20kPEG-SAP with fluorescein-conjugated trilysine in a molar ratio of about 1:1

and cyclosporine in an amount of about 360 μg,

in the form of a fiber that has an average length of about 2.5 mm to about 2.9 mm and an average diameter of not more than 0.62 mm in its dried state.

Assignments (2)
SECURITY INTEREST Recorded Aug 2, 2023
From: OCULAR THERAPEUTIX, INC.
To: BARINGS FINANCE LLC, AS AGENT
Reel/Frame 064476/0368 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 13, 2021
From: BLIZZARD, CHARLES D.; EL-HAYEK, RAMI; GOLDSTEIN, MICHAEL; JARRETT, PETER; VANSLETTE, ANDREW
To: OCULAR THERAPEUTIX, INC.
Reel/Frame 057776/0719 →
Continuity (3)
Provisional Application 63124204 · Dec 11, 2020
Provisional Application 63082505 · Sep 24, 2020
Related Publication 20220087931A1 · Mar 24, 2022